EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy

Antoine Gavoille iD, Anthime Flaus iD, Matthieu Dietz, Julie Pique, Antoine Seyve, Pierre Lardeux, Romain Marignier, Marc Janier, Pascal Sève

European Journal of Neurology · 2026-07 · 33 (7)

DOI: 10.1111/ene.70667 ↗

At a glance

Journal article in European Journal of Neurology, published online on 2026-07-14. Written by Antoine Gavoille and 8 co-authors. Institution: Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Centre de Référence des Maladies Inflammatoires Rares du…. Major MEDLINE topics: Positron Emission Tomography Computed Tomography, Sarcoidosis, Myelitis, Central Nervous System Diseases. 32 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction [ 18 F]FDG PET/CT scan is sometimes performed as part of the diagnostic evaluation of non‐compressive myelopathies, but the spinal cord lesion metabolism is not systematically evaluated. We aimed to investigate the diagnostic value of spinal cord lesion metabolism on [ 18 F]FDG PET/CT for differentiating inflammatory myelitis from neurosarcoidosis and tumoral lesions.

Methods

We conducted a retrospective cohort study of patients presenting with spinal cord lesions who underwent [ 18 F]FDG PET/CT. Patients were classified as primary inflammatory myelitis, neurosarcoidosis, tumoral lesions, or other etiologies. PET/CT examinations were reviewed by a nuclear medicine physician, masked to final diagnosis, who assessed the presence of hypermetabolism (qualitative analysis) and measured lesion SUV max , lesion‐to‐liver ratio, and level‐standardized Z ‐score to account for physiological uptake variability (quantitative analysis).

Results

A total of 106 patients were included: 60 (56.6%) with inflammatory myelitis, 20 (18.9%) with neurosarcoidosis, 10 (9.4%) with tumoral lesions, and 16 (15.1%) with other etiologies. Hypermetabolism was found in 80.0% of tumoral lesions, 50.0% of neurosarcoidosis, and 23.3% of inflammatory myelitis. PET/CT showed good performance in differentiating inflammatory myelitis or neurosarcoidosis from tumoral lesions using qualitative analysis (hypermetabolism: sensitivity 0.77, specificity 0.80, and 0.50, respectively) and quantitative analysis (SUV max : AUC 0.89 and 0.84, respectively). The performance of SUV max for distinguishing inflammatory myelitis from neurosarcoidosis was low (AUC 0.55), but improved with the lesion‐to‐liver ratio (AUC 0.64) and level‐standardized Z ‐score (AUC 0.65).

Conclusion

Spinal cord hypermetabolism on [ 18 F]FDG PET/CT demonstrated good performance for distinguishing tumoral lesions from inflammatory or neurosarcoidosis, but lower performance for differentiating inflammatory myelitis from neurosarcoidosis.

Subjects

MeSH terms (MEDLINE)

Positron Emission Tomography Computed TomographySarcoidosisMyelitisCentral Nervous System DiseasesSpinal CordSpinal Cord DiseasesSpinal Cord NeoplasmsHumansFemaleMaleFluorodeoxyglucose F18Retrospective StudiesMiddle AgedAgedAdultRadiopharmaceuticalsDiagnosis, Differential

Author keywords

[18F]FDG PET/CTmyelitismyelopathyneurosarcoidosisspinal cord tumor

Substances

Fluorodeoxyglucose F18Radiopharmaceuticals

Authors and institutions

  • Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (MIRCEM), Hôpital Neurologique Pierre Werthei…
  • CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Université Lyon 1, Villeurbanne, France.
  • Service de Biostatistique-Bioinformatique, Hospices Civils de Lyon, Lyon, France.
  • Département de médecine nucléaire, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
  • Université Claude Bernard Lyon 1, Lyon, France.
  • Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR5292, Lyon, France.

ORCID profiles: Antoine Gavoille, Anthime Flaus

Cite

APA

Gavoille, A., Flaus, A., Dietz, M., Pique, J., Seyve, A., Lardeux, P., Marignier, R., Janier, M., & Sève, P. (2026). Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70667

Vancouver

Gavoille A, Flaus A, Dietz M, Pique J, Seyve A, Lardeux P, et al. Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70667

BibTeX
@article{Gavoille2026,
  author = {Gavoille, Antoine and Flaus, Anthime and Dietz, Matthieu and Pique, Julie and Seyve, Antoine and Lardeux, Pierre and Marignier, Romain and Janier, Marc and Sève, Pascal},
  title = {Diagnostic Value of Spinal Cord Lesion Metabolism on [ 18 F ] FDG PET / CT for the Classification of Myelopathy},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/ene.70667}
}
Start for free →